Ka Shing Michael Cheung

Dr. Michael Ka Shing Cheung graduated from The University of Hong Kong in 2008, and received his Fellowship in Gastroenterology and Hepatology from the Hong Kong College of Physicians in 2015 and Fellowship from the Royal College of Physicians of Edinburgh in 2021. He obtained his Master of Public Health degree with distinction in 2016 and Doctor of Medicine degree (with Sir Patrick Manson Gold Medal) in 2020. He is currently the Clinical Assistant Professor in the Department of Medicine, the University of Hong Kong, Hong Kong. He is also the associate consultant in the University of Hong Kong-Shenzhen Hospital, Shenzhen, China, and honorary associate consultant in Queen Mary Hospital. Dr. Cheung’s research interests are gastrointestinal and hepatobiliary oncology (including gastric cancer, colorectal cancer, liver cancer), gut microbiota, gastrointestinal bleeding, inflammatory bowel disease, liver diseases (including hepatitis B virus, fatty liver, cirrhosis, liver cancer) and COVID-19 disease. He is experienced in various kinds of study design including randomized controlled trial, prospective cohort study, and retrospective cohort study (with particular focus on Big Data analysis). He has published 105 top international peer-reviewed journal articles since 2016, including first- or corresponding-authored articles in Gastroenterology (impact factor 33.883), Gut (impact factor 31.793), Diabetes Care (impact factor 17.152), Canadian Medical Association Journal (impact factor 16.859), Liver Cancer (impact factor 12.430), Journal of the National Cancer Institute (impact factor 11.816), Hypertension (impact factor 9.897), Alimentary Pharmacology & Therapeutics (impact factor 9.524), Hepatology International (impact factor 9.029), Clinical and Molecular Hepatology (impact factor 8.337), International Journal of Cancer (impact factor 7.316), Cancer (impact factor 6.921), Journal of Antimicrobial Chemotherapy (impact factor 5.758), World Journal of Gastroenterology (impact factor 5.374), Cancer Medicine (impact factor 4.711), Clinical and Translational Gastroenterology (impact factor 4.396) and Journal of Gastroenterology and Hepatology (impact factor 4.369). He was invited to deliver 55 presentations (including oral plenary session) and lectures at international and local conferences and institutions. He currently serves as an Editorial Board member in Artificial Intelligence in Gastroenterology. He has been invited to be the reviewer of 17 international journals including Gut, Clinical Gastroenterology & Hepatology, Alimentary Pharmacology & Therapeutics, British Journal of Cancer, Journal of Gastroenterology & Hepatology, Hepatology International, Gut Pathogens, Digestive Diseases & Sciences, Cancer Medicine and PLOS ONE.

Dr. Cheung was awarded the Professor Anthony Hedley Prize in Public Health for the highest place (with distinction in both written exam and thesis) in 2016 and the Sir Patrick Manson Gold Medal for his Doctor of Medicine in 2020. He received Travel Grant Award for abstract presentation at United European Gastroenterology Week in 2022, the National Scholar Award at United European Gastroenterology Week in 2021, Travel Grant Award for abstract presentation at United European Gastroenterology Week in 2019, APDWF/JGHG Young Investigator’s Award at Asian Pacific Digestive Week in 2017, Distinguished Research Paper Award for Young Investigator (2018 with Gold Medal Award, 2019, 2020 and 2021) from the Hong Kong College of Physicians, Faculty Outstanding Research Output Award (2018, 2019, 2020 and 2021) from the University of Hong Kong, Faculty Knowledge Exchange Award from the University of Hong Kong (2018), Best Abstract Award in Clinical Medicine in Medical Research Conference from the University of Hong Kong (2018, 2019, 2020 and 2021) as well as multiple other awards for abstract presentation in local and overseas conferences.

Dr. Cheung received the Health and Medical Research Fund (HMRF) from the Research Grant Council, the Government of HKSAR to conduct a research investigating the epidemiology, risk factors and chemopreventive agents of postcolonoscopy colorectal cancer in Hong Kong. He also received another HMRF to conduct a research investigating the epidemiology and risk factors of major osteoporotic fracture after Helicobacter pylori eradication and its interaction with proton pump inhibitors on fracture risk. In addition, he received an HMRF to conduct a commissioned research to investigate the role of gut microbiota in COVID-19 vaccine immunogenicity and adverse events.

Dr. Cheung was also the awardee of the Clinical Research Fellowship Programme and received the General Research Fund (GRF) from the Research Grant Council, the Government of HKSAR to conduct a 2-year project (2021-2022) which is a randomized controlled trial on treating fatty liver disease. In addition, he received another GRF to conduct a 3-year project (2022-2024) for a randomized controlled trial on preventing fibrosis and cirrhosis progression in chronic hepatitis B patients.

Research Profile

• Big Data analysis
• Epidemiology and chemoprevention of gastrointestinal and hepatobiliary cancers
• Helicobacter pylori infection
• Gastrointestinal bleeding
• Inflammatory bowel disease
• Liver diseases including hepatitis B virus infection, fatty liver and liver cancer
• Gut microbiota
• COVID-19 disease

Education

• Master of Public Health - MPH The University of Hong Kong (2014 — 2016)
• Bachelor of Medicine, Bachelor of Surgery - MBBS The University of Hong Kong (2002 — 2008)